ArticleJournal of assisted reproduction and genetics2026
Follicular kisspeptin-VEGF axis in polycystic ovary syndrome and ovarian hyperstimulation syndrome.
Article in Journal of assisted reproduction and genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePolycystic ovary syndrome (PCOS) and ovarian hyperstimulation syndrome (OHSS) are characterized by excessive follicular activity and profound alterations in the ovarian microenvironment. Kisspeptin and vascular endothelial growth factor (VEGF) play central roles in the regulation of folliculogenesis, angiogenesis, vascular permeability, and ovarian responsiveness. This study aimed to compare follicular fluid levels of Kisspeptin-1, Kisspeptin-54, and VEGF among women with PCOS, women who developed OHSS, and normoresponder controls, and to investigate their associations with established markers of ovarian response.
methodsIn this retrospective cross-sectional study, 90 women undergoing IVF treatment were stratified into three groups: normoresponder controls (n = 30), women with PCOS (n = 30), and patients who developed OHSS (n = 30). Follicular fluid samples were collected at the time of oocyte retrieval. Concentrations of Kisspeptin-1, Kisspeptin-54, and VEGF were quantified using validated enzyme-linked immunosorbent assay (ELISA) methods. Clinical, hormonal, and embryological parameters were collected and analyzed using group comparisons, correlation analyses, and multivariable logistic regression models.
resultsFollicular fluid concentrations of Kisspeptin-1, Kisspeptin-54, and VEGF differed significantly among study groups (all p < 0.001), demonstrating a progressive increase from normoresponder controls to women with PCOS and those who developed OHSS. Kisspeptin-54 and VEGF exhibited strong positive correlations with established indicators of ovarian response, including AMH, AFC, trigger-day estradiol levels, total oocyte yield, MII oocyte count, and the number of good-quality embryos (r = 0.41-0.78, all p < 0.001). In multivariable logistic regression analyses, Kisspeptin-54 (OR = 1.031) and VEGF (OR = 1.008), together with AFC, AMH, trigger-day estradiol, and total oocyte count, remained significantly associated with OHSS occurrence (all p < 0.01).
conclusionsFollicular fluid levels of Kisspeptin-1, Kisspeptin-54, and VEGF are significantly elevated in ovarian hyperresponse conditions and exhibit strong associations with key indicators of ovarian stimulation outcomes. These findings suggest that Kisspeptin-54 and VEGF reflect the biological features of ovarian hyperresponsiveness and may serve as complementary biomarkers of the follicular microenvironment, rather than clinically actionable predictors of OHSS.
Indexed as
Identifiers
42663893What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.